Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: May 13th, 2010 - May 13th, 2011

Statement of Need
This activity was developed for oncology physicians, nurses, and pharmacists who wish to enhance their competence concerning the treatment of patients with follicular lymphoma.

Target Audience
This activity was developed for physicians, nurses, and pharmacists.


Learning Objectives
At the completion of this activity participants should be able to:

  • Identify prognostic factors used to tailor treatment for patients with follicular lymphoma (FL)
  • Explain the role of maintenance therapy in the management of FL
  • Review appropriate strategies for preventing and/orminimizing common toxicities associated with newer FL therapies

Agenda - 1 hour
• Articles/Commentaries: 45 minutes
• Evaluation/Post-Test: 15 minutes

Physician Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.


Physician Credit Designation
Global Education Group designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.0 contact hour.


Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hours (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-10-016-H01-P.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner
or Manager
Company Reported Financial
Amanda Glazar, PhD Global Nothing to disclose
Jackie Dawson, MSN Global Nothing to disclose
Nancy Nesser, PharmD, JD MLI Nothing to disclose
Ryan Sims, CRNA, MS MLI Nothing to disclose
Dana Delibovi COEXM Nothing to disclose

Faculty Disclosures
*John P. Leonard,MD, is on the advisory board for and receives consulting fees from Biogen Idec, Biotest, Calistoga Pharmaceuticals, Celgene, Cell Therapeutics, Cephalon, EMD Serono, GlaxoSmithKline, Hospira, Johnson & Johnson, Millennium, Pfizer, and sanofi-aventis.

*PeterMartin,MD, is a consultant for Pfizer and on the speaker’s bureau for Genentech.

Alison Parker, PA, has nothing to disclose.

Cindy Ippoliti, PharmD, is on the speaker’s bureau for Eisai and Schering-Plough.

*Content will include non-FDA-approved uses.


The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Considerations in Multiple Myeloma Ask the Experts: Side Effect Management
Cindy Ippoliti, PharmD, Faiza Zafar, RPA-C, MPA, Ruben Niesvizky, MD
Supplements published on December 21, 2011
Considerations in Multiple Myeloma: Side Effect Management
Sagar Lonial, MD, Lillian Chou, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Cindy Ippoliti, PharmD, Lisa C. Smith, MSN, FNP, AOCN
Supplements published on November 24, 2008
Last modified: March 21, 2014